Neurocrine Biosciences, California, United States
Paul recieved his BS in Chemical Engineering from UCSB and MS in Biomedical Engineering from Case Western Reserve University before joining the Genomics Institute of the Novartis Research Foundation, bettern known as GNF, in 2005. He worked in the Advanced Automation Technologies group operating HTS systems and helping to develop and update systems for automated cell culture, high throughput flow cytometry and protein expression and purification. In 2018 he transitioned to Eli Lilly where he led a team embedded in Biologics Discovery tasked with developing and supporting several islands of automation performing molecular biology, plasmid purificaitons, mammalian expression and screening. In 2013 he joined Neurocrine as the Director of Enabling Technologies leading teams in HTS, Compound Management and Research Automation.
Disclosure information not submitted.
Next Generation Enabling Technologies
Monday, February 5, 2024
3:00 PM – 5:00 PM EST